Physician profile
Catherine Kier
NPI 1750328464
$176,243.57
in general payments reported to CMS, 2019-2025
16 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11K · 2021: $10K · 2022: $22K · 2023: $17K · 2024: $47K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Travel and Lodging: $11K · Food and Beverage: $3,877 · Consulting Fee: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,322.90 |
| Travel and Lodging | $10,907.34 |
| Food and Beverage | $3,877.34 |
| Consulting Fee | $1,485.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $112,491.02 | 2019-2025 | Dupixent |
| Genzyme Corporation | $61,732.65 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $352.05 | 2019-2024 | |
| Insmed, INC. | $306.81 | 2019 | |
| Mylan Specialty L.P. | $274.39 | 2023-2024 | Tobi Podhaler |
| Astrazeneca Pharmaceuticals LP | $218.39 | 2019-2022 | |
| Philips North America LLC | $149.00 | 2021-2025 | Vest Therapy Und |
| Gilead Sciences, INC. | $118.66 | 2019 | |
| Amgen INC. | $118.39 | 2022 | |
| Advanced Respiratory, INC | $113.64 | 2019 | |
| Axsome Therapeutics, INC. | $113.56 | 2025 | Sunosi |
| Glaxosmithkline, LLC. | $110.68 | 2019 | |
| Genentech, INC. | $58.73 | 2023 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $38.10 | 2024 | Lumryz |
| Regeneron Pharmaceuticals, INC. | $30.09 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Kier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.